1. Home
  2. ANAB vs SCL Comparison

ANAB vs SCL Comparison

Compare ANAB & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • SCL
  • Stock Information
  • Founded
  • ANAB 2005
  • SCL 1932
  • Country
  • ANAB United States
  • SCL United States
  • Employees
  • ANAB N/A
  • SCL N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • SCL Package Goods/Cosmetics
  • Sector
  • ANAB Health Care
  • SCL Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • SCL Nasdaq
  • Market Cap
  • ANAB 1.0B
  • SCL 998.2M
  • IPO Year
  • ANAB 2017
  • SCL N/A
  • Fundamental
  • Price
  • ANAB $42.39
  • SCL $46.15
  • Analyst Decision
  • ANAB Buy
  • SCL
  • Analyst Count
  • ANAB 12
  • SCL 0
  • Target Price
  • ANAB $63.80
  • SCL N/A
  • AVG Volume (30 Days)
  • ANAB 735.4K
  • SCL 197.8K
  • Earning Date
  • ANAB 11-04-2025
  • SCL 10-29-2025
  • Dividend Yield
  • ANAB N/A
  • SCL 3.48%
  • EPS Growth
  • ANAB N/A
  • SCL N/A
  • EPS
  • ANAB N/A
  • SCL 1.98
  • Revenue
  • ANAB $169,467,000.00
  • SCL $2,303,837,000.00
  • Revenue This Year
  • ANAB $37.52
  • SCL $8.89
  • Revenue Next Year
  • ANAB N/A
  • SCL $8.97
  • P/E Ratio
  • ANAB N/A
  • SCL $22.95
  • Revenue Growth
  • ANAB 196.42
  • SCL 5.35
  • 52 Week Low
  • ANAB $12.21
  • SCL $41.82
  • 52 Week High
  • ANAB $43.31
  • SCL $78.44
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 71.33
  • SCL 58.12
  • Support Level
  • ANAB $33.10
  • SCL $42.14
  • Resistance Level
  • ANAB $43.31
  • SCL $44.63
  • Average True Range (ATR)
  • ANAB 2.88
  • SCL 1.19
  • MACD
  • ANAB 0.51
  • SCL 0.41
  • Stochastic Oscillator
  • ANAB 91.49
  • SCL 95.56

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About SCL Stepan Company

Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.

Share on Social Networks: